PIK3CA and lung adenocarcinoma: In this study, the AKT p.E17K mutation was only detected in two lung adenocarcinomas with a BRAF p.V600E (c.1799 T > A) mutation, suggesting the cooperation between the MAPK and mTOR pathways, similar to that between the KRAS, NRAS or BRAF mutation and PIK3CA mutation.